Steven Cohen Alx Oncology Holdings Inc Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.84 - $17.56 $1.78 Million - $5.34 Million	304,100 New	304,100 $1.83 Million
Q4 2023 Feb 14, 2024	BUY	$4.81 - $15.38 $4.39 Million - $14.1 Million	913,700 New	913,700 $13.6 Million
Q1 2023 May 15, 2023	SELL	$4.52 - $11.71 $322,926 - $836,609	-71,444 Reduced 84.05%	13,556 $61,000
Q4 2022 Feb 14, 2023	SELL	$9.51 - $12.95 $2.83 Million - $3.85 Million	-297,500 Reduced 77.78%	85,000 $957,000
Q3 2022 Nov 14, 2022	BUY	$8.23 - $15.14 $3.15 Million - $5.79 Million	382,500 New	382,500 $3.66 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $68.9M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.